STOCK TITAN
  1. Home
  2. News
  3. OCUL

Ocular Therapeutix Inc - OCUL STOCK NEWS

Welcome to our dedicated news page for Ocular Therapeutix (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeutix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocular Therapeutix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocular Therapeutix's position in the market.

News
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
Rhea-AI Summary
AffaMed Therapeutics announces acceptance of DEXTENZA NDA by Singapore Health Sciences Authority for treating ocular inflammation and pain following ophthalmic surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
Rhea-AI Summary
Ocular Therapeutix, Inc. appoints Steve Meyers as Chief Commercial Officer, showcasing dedication to expanding their drug portfolio for eye-related conditions. Meyers brings over 20 years of commercial experience to drive Ocular's commercial efforts forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
management
-
News
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
Rhea-AI Summary
Ocular Therapeutix, Inc. announces the initiation of Phase 3 SOL-1 clinical trial for AXPAXLI in wet age-related macular degeneration (AMD). The trial aims to evaluate the efficacy and safety of the treatment, potentially reducing the need for frequent injections and office visits for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
clinical trial
News
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that the U.S. FDA has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal Phase 3 SOL clinical trial of AXPAXLI™ for the treatment of wet age-related macular degeneration (wet AMD). The amendment expands eligibility criteria, allowing treatment-naïve wet AMD subjects with visual acuity of approximately 20/80 or better to enroll in the trial. The modification also permits the trial to move forward with a single optimized implant with a drug load of 450 µg of a more soluble form of axitinib, aimed at accelerating the enrollment process and improving drug release synchronization with hydrogel bioresorption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.98%
Tags
clinical trial
-
News
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Rhea-AI Summary
Ocular Therapeutix, Inc. (Nasdaq: OCUL) closed a public offering of 35,420,000 shares of its common stock at a price of $3.25 per share, generating approximately $115.1 million in gross proceeds. The company plans to use the net proceeds for the Phase 3 clinical development of AXPAXLI for the treatment of wet AMD and other clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
offering
-
News
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
Rhea-AI Summary
Ocular Therapeutix™, Inc. (Nasdaq: OCUL) announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 4,620,000 shares. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
offering
News
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) has commenced an underwritten public offering of its common stock, with an option for underwriters to purchase additional shares. The company plans to use the proceeds to fund the Phase 3 clinical development of AXPAXLI for the treatment of wet AMD and support other clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
offering
-
News
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its participation in upcoming healthcare conferences including Jefferies London Healthcare Conference, BTIG 3rd Annual Ophthalmology Day, and Piper Sandler 35th Annual Healthcare Conference. Management will be available for investor meetings, and live webcasts of the fireside chats will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
conferences
-
News
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
Rhea-AI Summary
OCUL: FDA agrees to pivotal trial design for AXPAXLI in wet AMD and non-proliferative diabetic retinopathy. Q3 2023 DEXTENZA revenue grows 26% to $15.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
earnings
News
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
Rhea-AI Summary
Ocular Therapeutix, Inc. has received written agreement from the FDA for the design of its Phase 3 clinical trial for AXPAXLI, an intravitreal implant for the treatment of wet age-related macular degeneration (wet AMD). The trial, referred to as the SOL trial, aims to enroll approximately 300 treatment-naïve wet AMD subjects and will be conducted primarily at U.S. sites. The Company expects to dose the first subject by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.93%
Tags
clinical trial
Stock OCUL logo
Ocular Therapeutix Inc

Nasdaq:OCUL

OCUL Rankings

#2310 Ranked by Market Cap
#4005 Ranked by Stock Gains
N/A Ranked by Dividends

OCUL Stock Data

1.19B
128.47M
3.68%
50.09%
7.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bedford

About OCUL

ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib